Guillermo Fernández-Varo

Research group

Translational research group in new therapeutic and diagnostic strategies in liver diseases Accredited researcher (R3A-CIBER)

guillermo.fernandez@ciberehd.org 0000-0002-7776-3300

Featured publications

Liver-targeted nanoparticles delivering nitric oxide reduce portal hypertension in cirrhotic rats

Authors:
Perramón, M; Navalón-López, M; Fernández-Varo, G; Moreno-Lanceta, A; García-Pérez, R;

(...)

García-Villoria, J; Morales-Ruiz, M; Melgar-Lesmes, P; Borrós, S; Jiménez, W.

Reference: Biomedicine & Pharmacotherapy 2024.
Partial vasopressin 1a receptor agonism reduces portal hypertension and hyperaldosteronism and induces a powerful diuretic and natriuretic effect in rats with cirrhosis and ascites

Authors:
Fernández-Varo, G; Jiménez, W; Cable, E; Ginès, P; Harris, G;

Bukofzer, S.

Reference: Biomedicine & Pharmacotherapy 2023.
The pituitary tumor-transforming gene 1 / delta like homolog 1 pathway plays a key role in liver fibrogenesis

Authors:
Perramón, M; Carvajal, S; Reichenbach, V; Fernández-Varo, G; Boix, L;

(...)

Melgar-Lesmes, P; Bruix, J; Melmed, S; Lamas, S; Jiménez, W.

Reference: Liver International 2022.
Validation of a Gas Chromatography-Mass Spectrometry Method for the Measurement of the Redox State Metabolic Ratios Lactate/Pyruvate and β-Hydroxybutyrate/Acetoacetate in Biological Samples

Authors:
Wijngaard, R; Perramón, M; Parra-Robert, M; Hidalgo, S; Butrico, G;

(...)

Jiménez, W; Fernández-Varo, G; Shulman, GI; Cline, GW; Casals, G.

Reference: International Journal Of Molecular Sciences 2021.
Bespoken nanoceria: A new effective treatment in experimental hepatocellular carcinoma

Authors:
Fernández-Varo G; Perramón M; Carvajal S; Oró D; Casals E;

(...)

Fuster J; Garcia-Valdecasas JC; Pavel MC; Puntes V; Jiménez W .

Reference: Hepatology 2020.
Cerium oxide nanoparticles display antilipogenic effect in rats with non-alcoholic fatty liver disease

Authors:
Carvajal S; Perramón M; Oró D; Casals E; Fernández-Varo G;

(...)

Ribera J; Pastor Ó; Morales-Ruíz M; Puntes V; Jiménez W.

Reference: Scientific Reports 2019.
Cerium oxide nanoparticles reduce steatosis, portal hypertension and display antiinflammatory properties in rats with liver fibrosis

Authors:
Oró D; Yudina T; Fernández-Varo G; Casals E; Reichenbach V;

(...)

González de la Presa B; Sandalinas S; Carvajal S; Puntes V; Jiménez W .

Reference: Journal Of Hepatology 2016.
Vasopressin 1a receptor partial agonism increases sodium excretion and reduces portal hypertension and ascites in cirrhotic rats

Authors:
Fernández-Varo G; Oró D; Cable EE; Reichenbach V; Carvajal S;

de la Presa BG; Wi?niewski K; Ginés P; Harris G; Jiménez W .

Reference: Hepatology 2016.
Serological markers of fibrosis

Authors:
Fernandez-Varo; G;

Reference: Gastroenterologia Y Hepatologia 2012.
Adenoviral dominant-negative soluble PDGFRbeta improves hepatic collagen, systemic hemodynamics, and portal pressure in fibrotic rats

Authors:
Reichenbach, V; Fernandez-Varo, G; Casals, G; Oro, D; Ros, J;

Melgar-Lesmes, P; Weiskirchen, R; Morales-Ruiz, M; Jimenez, W.

Reference: Journal Of Hepatology 2012.

Featured Projects

THERANANO: Determining the therapeutic use in liver diseases of advanced antioxidant conjugates based on cerium oxide nanoparticles

Principal investigator: Gregori Casals Mercadal, Guillermo Fernandez Varo

Funder: Subdireccion General de Evaluacion y Fomento de la Investigacion ; IDIBAPS-HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA (Participant) (Participante)

Code: PI19/00774

Duration: 01/01/2020 - 31/12/2022
Utilidad terapéutica de las nanopartículas de óxido de cerio en las enfermedades hepáticas.

Principal investigator: Wladimiro Jimenez Povedano, Guillermo Fernandez Varo

Funder: Ministerio de Economía y Competitividad. SAF2015-64126-R ; HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA (Participante)

Code: SAF2015-64126-R

Duration: 01/01/2016 - 31/12/2018
Regeneración tisular, vasodilatación esplácnica y biomarcadores de fibrosis en las enfermedades hepáticas. Evaluación en pacientes y modelos experimentales con fibrosis.

Principal investigator: Wladimiro Jiménez Povedano

Funder: Ministerio de Economía y Competitividad. SAF2012-35979 ; HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA (Participante)

Duration: 01/01/2013 - 31/12/2015

Guillermo Fernández-Varo

Research group

Featured publications

Featured Projects

THERANANO: Determining the therapeutic use in liver diseases of advanced antioxidant conjugates based on cerium oxide nanoparticles

Utilidad terapéutica de las nanopartículas de óxido de cerio en las enfermedades hepáticas.

Regeneración tisular, vasodilatación esplácnica y biomarcadores de fibrosis en las enfermedades hepáticas. Evaluación en pacientes y modelos experimentales con fibrosis.

Subscribe to the Newsletter of Clínic